All In Biotech

Drug Trial Radar · NCT00858871

First Line Hepato Cellular Carcinoma (HCC)

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,714 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,714

Actual

Start

May 2009

Primary completion

Jun 2012

Study completion Sep 2013

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.

Conditions

  • Hepato Cellular Carcinoma (HCC)

Interventions

  • BrivanibDrug

    Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity

  • PlaceboDrug

    Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity

  • SorafenibDrug

    Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity

  • PlaceboDrug

    Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatmentTime frame: Survival will be assessed continuously

Locations

173 sites in 26 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • Univ Of Ark For Med Sci

    Little Rock, Arkansas

  • Agajanian Institute Of Hematology And Oncology

    Downey, California

  • Sharp Clinical Oncology Research

    San Diego, California

  • Va Ct Healthcare System

    West Haven, Connecticut

  • Medical Specialists Of Palm Beaches

    Lake Worth, Florida

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • 3912 Taubman Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Thomas Jefferson Univ.

    Philadelphia, Pennsylvania

  • Mcguire Dvamc

    Richmond, Virginia

  • University Of Wisconsin

    Madison, Wisconsin

  • Local Institution

    Buenos Aires, Buenos Aires, Argentina

  • Local Institution

    Caba, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Rosario, Santa Fe Province, Argentina

  • Local Institution

    Camperdown, New South Wales, Australia

  • Local Institution

    Concord, New South Wales, Australia

  • Local Institution

    Westmead Nsw, New South Wales, Australia

  • Local Institution

    Parkville, Victoria, Australia

  • Local Institution

    Prahan, Victoria, Australia

  • Local Institution

    Liège, Belgium

  • Local Institution

    Fortaleza, Ceará, Brazil

  • Local Institution

    Salvador, Estado de Bahia, Brazil

  • Local Institution

    Salvador - Ba, Estado de Bahia, Brazil

  • Local Institution

    Goiânia, Goiás, Brazil

  • Local Institution

    Divinópolis, Minas Gerais, Brazil

  • Local Institution

    Curitiba, Paraná, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Barretos, São Paulo, Brazil

  • Local Institution

    Jaú, São Paulo, Brazil

  • Local Institution

    São Paulo, São Paulo, Brazil

  • Local Institution

    Calgary, Alberta, Canada

  • Local Institution

    Vancouver, British Columbia, Canada

  • Local Institution

    London, Ontario, Canada

  • Local Institution

    Montreal, Quebec, Canada

  • Local Institution

    Beijing, Beijing Municipality, China

  • Local Institution

    Beijing, Beijing Municipality, China

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.